Credit Suisse Group reaffirmed their outperform rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a research report sent to investors on Wednesday morning, Briefing.com Automated Import reports.
A number of other brokerages also recently weighed in on ALNA. Cowen reiterated a buy rating on shares of G1 Therapeutics in a report on Friday, May 10th. Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a report on Wednesday, May 15th. Finally, Wedbush reiterated a buy rating and set a $36.00 price target on shares of Allena Pharmaceuticals in a report on Tuesday, July 2nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $21.67.
Shares of ALNA stock opened at $4.94 on Wednesday. Allena Pharmaceuticals has a 1-year low of $3.92 and a 1-year high of $12.38. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.24. The company’s fifty day simple moving average is $4.55.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALNA. Rhumbline Advisers acquired a new position in shares of Allena Pharmaceuticals during the 4th quarter worth about $78,000. BlackRock Inc. lifted its position in shares of Allena Pharmaceuticals by 0.8% during the 4th quarter. BlackRock Inc. now owns 581,971 shares of the company’s stock worth $3,172,000 after purchasing an additional 4,528 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Allena Pharmaceuticals by 8.1% during the 4th quarter. Geode Capital Management LLC now owns 72,314 shares of the company’s stock worth $394,000 after purchasing an additional 5,444 shares during the last quarter. Sphera Funds Management LTD. lifted its position in shares of Allena Pharmaceuticals by 16.9% during the 4th quarter. Sphera Funds Management LTD. now owns 345,199 shares of the company’s stock worth $1,881,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Allena Pharmaceuticals by 3.8% during the 4th quarter. Squarepoint Ops LLC now owns 43,500 shares of the company’s stock worth $237,000 after purchasing an additional 1,600 shares during the last quarter. 79.71% of the stock is owned by hedge funds and other institutional investors.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Read More: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.